

Summary of status of development and availability of variant¹ influenza A(H3N2) candidate vaccine viruses and potency testing reagents

26 September 2019

Candidate vaccine viruses

Antigenic prototype	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
	Wild type virus			WHO CCs
A/Minnesota/11/2010	NYMC X-203*	Classical	NYMC, USA	CDC, USA NYMC, USA
	NYMC X-203A*	Classical	NYMC, USA	CDC, USA NYMC, USA
A/Indiana/10/2011	Wild type virus			WHO CCs
	NYMC X-213*	Classical	NYMC, USA	CDC, USA NYMC, USA
A/Ohio/28/2016	IDCDC-RG55C*	Reverse genetics	CDC, USA	CDC, USA

^{*}These viruses are candidate vaccine viruses which have passed relevant safety testing. They can be handled under BSL-2 enhanced containment².

Candidate vaccine viruses in preparation

Antigenic prototype	Type of virus or reassortant	Developing Institute	Available from
A/Ohio/28/2016	Classical	NIBSC, UK	Pending
A/Ohio/13/2017-like	Reverse genetics	CDC, USA	Pending

Institutes contact details for candidate vaccine viruses orders/information:

CDC: <u>dwentworth@cdc.gov</u> (Subject: CVV request)

NIBSC: <u>standards@nibsc.org</u> or enquiries@nibsc.org

NYMC: <u>doris bucher@nymc.edu</u>

WHO CCs: http://www.who.int/influenza/gisrs_laboratory/collaborating_centres/list/en/

For general enquiries, please contact gisrs-whohq@who.int

For other candidate vaccine viruses and potency testing reagents, please go to

http://www.who.int/influenza/vaccines/virus/en/

¹ Joint FAO, OIE, WHO announcement of the standardization of terminology for the variant A(H3N2) virus recently infecting humans at http://www.who.int/influenza/gisrs_laboratory/terminology_ah3n2v/

http://www.who.int/biologicals/publications/trs/areas/vaccines/influenza/Annex%205%20human%20pandemic%20influenza.pdf?ua=1